Viatris Misses Estimates, Cash Flow Up
Viatris reported mixed results for Q4 2024, missing revenue and EPS expectations, despite noteworthy debt reduction and portfolio adjustments.
Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt reduction and strategic advancements, Viatris fell short of analysts' forecasts. The adjusted earnings per share (EPS) stood at $0.54, missing the estimated $0.56, while total revenue reached $3,528 million, trailing the predicted $3,592 million.
Although its internal targets were achieved, the external market expectations were not met, reflecting a quarter with both strategic progress and financial challenges.
Source: Analyst estimates for the quarter provided by FactSet.
